Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedEL
EQT Life Sciences
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Enterprise software · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $267M 2 disclosed · full round size, not this investor’s share